Search results for "Buserelin"

showing 10 items of 10 documents

Gene Expression and Apoptosis Levels in Cumulus Cells of Patients with Polymorphisms of FSHR and LHB Undergoing in Vitro Fertilization Program

2017

Background/Aims: FSH receptor (FSHR) Ala307Thr and Asn680Ser and LHβ chain (LHB) Trp28Arg and Ile35Thr polymorphisms affect the response to pharmacological ovarian stimulation with r-FSH in women undergoing assisted reproductive treatment (ART). Here, we evaluated the expression level of selected genes involved in follicle maturation and the possible onset of apoptosis in cumulus cells of patients with single and double FSHR and LHB polymorphisms, as potential markers of oocyte competence. Methods: Cumulus cells from 36 stimulated patients were collected and SNP genotyping performed by PCR. Gene expression was evaluated through real-time PCR, and apoptosis estimated via TUNEL assay, and cle…

0301 basic medicineApoptosis; Cumulus cells; FSHR; Gene expression; LH; Polymorphism; PhysiologyLHPhysiologyApoptosislcsh:PhysiologyGonadotropin-Releasing Hormone0302 clinical medicineGene FrequencyFSHRGene expressionlcsh:QD415-436Settore BIO/06 - Anatomia Comparata E CitologiaCells CulturedIn Situ Hybridization Fluorescence030219 obstetrics & reproductive medicinelcsh:QP1-981Caspase 3Apoptosis; Cumulus cells; FSHR; Gene expression; LH; Polymorphismmedicine.anatomical_structureCumulus cellReceptors FSHDNA fragmentationFemaleSignal TransductionAdultHeterozygotemedicine.medical_specialtyendocrine systemGenotypeGranulosa cellCumulus cellsDNA FragmentationFertilization in VitroBiologyReal-Time Polymerase Chain ReactionBuserelinPolymorphism Single Nucleotidelcsh:Biochemistry03 medical and health sciencesFollicleInternal medicinemedicineHumansPolymorphismApoptosiHeterozygote advantageLuteinizing Hormone beta SubunitOocyte030104 developmental biologyEndocrinologyHaplotypesApoptosisMultivariate AnalysisOocytesGene expressionFollicle-stimulating hormone receptorProto-Oncogene Proteins c-aktCellular Physiology and Biochemistry
researchProduct

Characteristics of urinary luteinizing hormone (LH) during the induction of LH surges of different magnitude in blood

1995

Urinary luteinizing hormone (LH) testing has been proposed as a reliable method for the prediction of ovulation but its accuracy has been challenged by some studies. To check how accurately the oscillations of urinary LH reflected the plasma changes, surges of LH of different magnitude and duration were artificially induced in plasma and the hormone was measured simultaneously in urine. Post-menopausal women (n = 16) were stimulated during 1 week with a combination of transdermal oestradiol (400 micrograms) and i.m. progesterone (25 mg on day 4, 50 mg on day 5) to obtain an LH discharge comparable with the pre-ovulatory LH peak. A short and moderate peak of LH was induced by the i.v. inject…

Adultmedicine.medical_specialtyTime Factorsmedicine.drug_classmedia_common.quotation_subjectRadioimmunoassayGonadotropin-releasing hormoneUrineBuserelinSensitivity and SpecificityGonadotropin-Releasing HormoneAndrologyInternal medicinemedicineHumansOvulationProgesteronemedia_commonOvulation DetectionEstradiolChemistryEstrogen Replacement TherapyRehabilitationReproducibility of ResultsObstetrics and GynecologyLuteinizing HormoneMiddle Agedmedicine.diseaseBuserelinMenopauseEndocrinologyReproductive MedicineFemaleMenopauseGonadotropinLuteinizing hormonemedicine.drugHormoneHuman Reproduction
researchProduct

Influence of the ovary on parameters of LH secretion during the recovery from buserelin-induced desensitization

1994

Abstract This study examined the effect of the ovary on LH pulsatility and on the secretory performance of gonadotrophes during the phase of recovery after treatment with buserelin, a GnRH analogue. We included 12 patients, who received buserelin (1.2 mg/day, intranasally for 3 months) as a reductive therapy for uterine leiomyomatosis prior to hysterectomy. Six patients were oophorectomized and the other 6 patients had their ovaries preserved. LH was measured in samples taken basally up to 36 days after suppression of buserelin. LH pulsatility was studied on day 9 along a 24-h cycle, and the response of the hormone to a double-stimulus GnRH test on days 0, 9, 20, and 34. The concentration o…

Adultmedicine.medical_specialtymedicine.drug_classOvariectomymedicine.medical_treatmentRadioimmunoassayUterusEndogenyHysterectomyBuserelinLeiomyomatosisInternal medicinemedicineHumansAdministration IntranasalHysterectomybusiness.industryOvaryRemission InductionObstetrics and GynecologyOophorectomyLuteinizing HormoneMiddle AgedBuserelinEndocrinologymedicine.anatomical_structurePremenopauseReproductive MedicineIn uteroUterine NeoplasmsFemaleGonadotropinbusinessmedicine.drugHormoneEuropean Journal of Obstetrics & Gynecology and Reproductive Biology
researchProduct

Concomitant gonadotropin-releasing hormone agonist and menotropin treatment for the synchronized induction of multiple follicles.

1988

In an effort to overcome possible interference by endogenous gonadotropin-ovarian hormone dynamics, desensitization of the pituitary gonadotropins by a gonadotropin-releasing hormone agonist (GnRHa) was achieved in 12 women with repeatedly failed attempts at multiple follicular stimulation. Eight women were scheduled for in vitro fertilization (IVF) and embryo transfer (ET), and 4 for gamete intrafallopian transfer (GIFT). Stimulation failure was characterized by premature luteinization, poor estradiol (E2) response, or inadequate follicular growth. The agonist was administered by nasal spray 500 to 600 micrograms/day beginning on days 21 to 23 of the menstrual cycle. A rapid desensitizatio…

AgonistAdultendocrine systemmedicine.medical_specialtyMenotropinsmedicine.drug_classmedia_common.quotation_subjectmedicine.medical_treatmentFertilization in VitroBiologyBuserelinReproductive TechniquesOvulation InductionInternal medicineGonadotropin-releasing hormone agonistFollicular phasemedicineHumansGamete intrafallopian transferMenstrual cyclemedia_commonIn vitro fertilisationObstetrics and GynecologyEmbryo TransferEmbryo transferEndocrinologyReproductive MedicineFemaleMenotropinhormones hormone substitutes and hormone antagonistsFertility and sterility
researchProduct

Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist…

2005

Background This descriptive study evaluates the impact on endometrial development of standard and high doses of a GnRH antagonist in stimulated cycles compared with GnRH agonist and natural cycles. Methods Thirty-one oocyte donors were treated with a combination of rFSH and 0.25 mg/day ganirelix (standard dose), 2 mg/day ganirelix (high dose) or 0.6 mg/day buserelin (long protocol). Vaginal progesterone (200 mg/day) was administered in the luteal phase. Endometrial biopsies were performed 2 and 7 days after HCG administration. Additional biopsies were carried out in a subset of 12 subjects, 2 and 7 days following the LH peak of their previous natural cycle. Biopsies were evaluated histologi…

AgonistAdultendocrine systemmedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classmedicine.medical_treatmentFertilization in VitroLuteal phaseBiologyLuteal PhaseEndometriumBuserelinChorionic GonadotropinGonadotropin-releasing hormone antagonistGonadotropin-Releasing HormoneEndometriumOvulation InductionInternal medicinemedicineHumansUltrasonicsGanirelixOligonucleotide Array Sequence Analysismedicine.diagnostic_testOocyte DonationRehabilitationObstetrics and GynecologyBuserelinmedicine.anatomical_structureEndocrinologyReproductive MedicineGene Expression RegulationReceptors EstrogenMicroscopy Electron ScanningOocytesRNAOvulation inductionFemaleFollicle Stimulating HormoneReceptors Progesteronehormones hormone substitutes and hormone antagonistsmedicine.drugEndometrial biopsyHuman reproduction (Oxford, England)
researchProduct

In vitro pulsatile and continuous transdermal delivery of buserelin by iontophoresis

1993

Abstract Transdermal delivery of buserelin, a nonapeptide, from hydroxyethylcellulose hydrogel through isolated human stratum comeum was studied. In vitro studies were carried out in a drug release apparatus (DAB 10/USP XII) using self designed rotary disk cells equipped with platinum electrodes. Different forms of current were examined. A pulsatile application of continuous current resulted in a step-like permeation profile. Different on/off ratios (5 min/55 min; 10 min/50 min; 15 min/45 min)) were studied. When continuous non-interrupted current with different current densities (0.1–0.3 mA·cm −2 ) was applied, linear dependence of the final cumulative amount of buserelin on current durati…

IontophoresisStereochemistryChemistryDirect currentPharmaceutical SciencePermeationBuserelinDosage formIonic strengthmedicineCurrent densityNuclear chemistrymedicine.drugTransdermalJournal of Controlled Release
researchProduct

Endocrine and Clinical Evaluation of 107 Patients With Advanced Prostatic Carcinoma Under Long-Term Pernasal Buserelin or Intramuscular Decapeptyl De…

1988

Three major assumptions emerged from these clinical and endocrine long-term studies. First, buserelin, given pernasally in the conventional doses, and Decapeptyl microcapsules administered intramuscularly in 5-week intervals are equally effective in terms of their long-term castration effect in previously untreated patients with prostatic carcinoma. However, Decapeptyl causes complete LH and subsequent testosterone down-regulation 1 week earlier than buserelin. Furthermore, this treatment is more convenient, and the compliance is better. Both LHRH analogues are equally well tolerated. Second, in groups of prostate cancer patients with far advanced disease treated with palliative intention, …

OncologyCancer Researchmedicine.medical_specialtybusiness.industryUrologymedicine.diseaseBuserelinchemistry.chemical_compoundProstate cancerCastrationOncologychemistryInternal medicineCarcinomaMedicineEndocrine systembusinessClinical evaluationDecapeptyl DepotTestosteronemedicine.drugAmerican Journal of Clinical Oncology
researchProduct

Binding of Cu2+, Zn2+, and Ni(2+)-GnRH complexes with the rat pituitary receptor.

1997

Complex of copper with the gonadotropin-releasing hormone, GnRH, competed more efficiently for the GnRH receptor than native GVRH, while complexes of nickel with GnRH and zinc with GnRH had slightly lower affinity. Copper ion added to the incubation mixture inhibited the buserelin binding to the receptor.

endocrine systemmedicine.medical_specialtyKineticschemistry.chemical_elementGonadotropin-releasing hormoneZincBiochemistryBinding CompetitiveBuserelinInorganic ChemistryGonadotropin-Releasing HormoneNickelPituitary Gland AnteriorInternal medicinemedicineAnimalsReceptorIncubationChemistryCopperBuserelinRatsKineticsZincEndocrinologyhormones hormone substitutes and hormone antagonistsCopperReceptors LHRHmedicine.drugHormoneJournal of inorganic biochemistry
researchProduct

Endoscopic management of a case of 'complete septate uterus with unilateral haematometra'

1995

Endoscopy and ultrasound was used to diagnose a 13 year old virgin girl who presented with dysmenorrhoea and suspected right side adnexal tumescence. The girl was found to have a complete septate uterus with non-communicating right hemicavity and haematometra, an exceptional type of Mullerian anomaly. After pretreatment with buserelin, hysteroscopic metroplasty was successfully performed.

medicine.medical_specialtyAdolescentUterusHysteroscopyBuserelinDysmenorrheaHematometraMedicineHumansUltrasonographyHematometraTumescencemedicine.diagnostic_testbusiness.industryRehabilitationUterusObstetrics and Gynecologymedicine.diseaseCombined Modality TherapyBuserelinEndoscopySurgerymedicine.anatomical_structureTreatment OutcomeReproductive MedicineHysteroscopyFemalebusinessHaematometraSeptate uterusmedicine.drug
researchProduct

Gonadotropin-releasing hormone analogues for palliation of carcinoma of the prostate

1983

Since the introduction of contrasexual treatment as the basic concept of palliation of prostatic carcinoma in the 1940's, orchiectomy, estrogens, and, in recent years, antiandrogens have become generally accepted treatment forms. Three facts: 1) estrogen treatment being at best palliative and at worst dangerous; 2) surgical castration having psychological impacts, at least in the younger age group; and 3) both being probably ineffective from the beginning, have led us to investigate an alternative of minimal toxicity and possible reversibility in the initial treatment of advanced prostatic carcinoma. 12 patients with far advanced carcinoma of the prostate were treated with the gonadotropin …

medicine.medical_specialtybusiness.industrymedicine.drug_classUrologymedicine.medical_treatmentUrologyGonadotropin-releasing hormonemedicine.diseaseBuserelinSurgerymedicine.anatomical_structureProstateEstrogenmedicineCarcinomaOrchiectomybusinessTestosteroneGonadotropin-releasing hormone analoguemedicine.drugWorld Journal of Urology
researchProduct